A Case for Anti-IgE Vaccination

Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high-affinity receptor FcεRI on mast cells and basophils, where allergen-induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research. Nevertheless, monoclonal anti-IgE therapy with omalizumab has transformed allergy treatment and proven to be safe and effective in various allergic indications. A remaining limitation of omalizumab is its high cost and requirement for repeated dosing, which limits accessibility. Vaccination against IgE theoretically offers a promising, cost-effective alternative, but long-standing safety concerns have slowed its development. Here, we review emerging concepts in IgE biology and therapeutic IgE neutralization. Recent research demonstrates that vaccine-induced anti-IgE antibodies can selectively neutralize free IgE while sparing FcεRI-bound IgE, thereby avoiding effector cell activation. This mechanism mirrors the behavior of natural anti-IgE autoantibodies, which may regulate physiological IgE homeostasis. Together, these novel insights indicate that anti-IgE vaccination is safe, biologically grounded, and a compelling strategy for the long-term control of IgE-mediated allergic disease.